by | Apr 13, 2022 | Colonna, Marco, Secca da Silva, Cristiane
— Disease indication – Autoimmune diseases (plaque psoriasis, psoriatic arthritis, Crohn’s disease)
Drug format – Monoclonal antibody
Drug class – First-in-class
Research stage and preliminary data – Researchers have stimulated human ILC3s with IL-23 in vitro, with and…
by | Apr 13, 2022 | Colonna, Marco, Secca da Silva, Cristiane
— Disease indication – Autoimmune diseases (plaque psoriasis, psoriatic arthritis, Crohn’s disease)
Drug format – Monoclonal antibody
Drug class – First-in-class
Research stage and preliminary data – Researchers have stimulated human ILC3s with IL-23 in vitro, with and…
by | Mar 30, 2022 | Gelman, Andrew, Puyo, Carlos
— Technology Description
Researchers at Washington University in St. Louis have developed a drug combination that can be used to prevent tissue injury resulting from placement of a variety of medical devices including, but not limited to, endotracheal tubes (ETTs) and catheters (bladder catheters). P…
by | Mar 10, 2022 | DiPersio, John, Persaud, Stephen "Steve"
— Technology Description
Researchers at Washington University in St. Louis have developed an improved process for conditioning patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) using JAK inhibitors. Commonly used to treat autoimmune diseases like rheumatoid arthritis, JAK inh…
by | Mar 2, 2022 | Lim, Kian-Huat, Liu, Yongjian, Zhang, Xiaohui
— Disease indication –
Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide
Drug class – First-in-class
Target – CCR2, the receptor for CCL2
Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…